Cimetidine pharmacokinetics in patients with Zollinger-Ellison syndrome.

Abstract

Although most patients with Zollinger-Ellison syndrome can be effectively treated with histamine H2-receptor antagonists, many patients require large doses of drug to inhibit gastric acid secretion adequately. The purpose of the present study was to compare the pharmacokinetics of a 1200-mg oral dose of cimetidine in 9 patients with Zollinger-Ellison syndrome requiring more than 2.4 g/day of cimetidine with 5 age-matched normal volunteers receiving intravenous pentagastrin infusions. Poor responsiveness to cimetidine in patients with Zollinger-Ellison syndrome has several different causes. The concentration of cimetidine in the blood required to inhibit gastric acid secretion by 50% was markedly increased in 3 of the patients with Zollinger-Ellison syndrome, suggesting parietal cell resistance. One patient showed a substantial decrease in cimetidine absorption and 4 patients had delayed cimetidine absorption. Thus 7 of the 9 patients with Zollinger-Ellison syndrome who required more than 2.4 g/day of cimetidine to inhibit gastric acid secretion had abnormal cimetidine pharmacokinetics.

• Authors: K E McArthur, J P Raufman, J J Seaman, J A Ziemniak, J D Gardner, R T Jensen
• Journal: Gastroenterology (Gastroenterology) Vol. 93 Issue 1 Pg. 69-76 (Jul 1987) ISSN: 0016-5085 [Print] United States
• PMID: 3582917 (Publication Type: Journal Article)

Chemical References

• Cimetidine

Topics

• Adult
• Aged
• Cimetidine (administration & dosage, metabolism)
• Drug Resistance
• Female
• Gastric Acid (metabolism)
• Half-Life
• Humans
• Intestinal Absorption
• Kinetics
• Male
• Metabolic Clearance Rate
• Middle Aged
• Zollinger-Ellison Syndrome (drug therapy, metabolism)